Maxim Group initiated coverage of Stealth BioTherapeutics (NASDAQ:MITO) with a “buy” rating and price target of $3. The stock closed at $1.56 on June 30. Stealth is developing compounds that target mitochondrial...
Cantor Fitzgerald launched coverage of Sanara MedTech (NASDAQ:SMTI) with an “overweight” rating and a 12-month price target of $45. The stock closed at $36.66 on June 29. Sanara has built a portfolio of differentiated...
Research Capital initiated coverage of Perimeter Medical Imaging (TSXV:PINK) with a “speculative buy” rating and a 12-month price target of $4.90 (Canadian). The stock closed at $3.37 on June 28. Perimeter is a medical...
Cantor Fitzgerald initiated coverage of Lipocine (NASDAQ:LPCN) with an “overweight” rating and 12-month price target of $3. The stock closed at $1.36 on June 23. “We think Lipocine has multiple shots on goal across its...
Cantor Fitzgerald launched coverage of Evelo Biosciences (NASDAQ:EVLO) with an “overweight” rating and 12-month price target of $28. The stock closed at $16.08 on June 22. Evelo is developing oral therapies derived from...
Maxim Group initiated coverage of OSE Immunotherapeutics (NXT PA:OSE) with a “buy” rating and $22 price target. The stock closed at $13.56 on June 22. Analyst Naureen Quibria, Ph.D., writes that French-based OSE has a...
Alliance Global Partners raised its price target for ReShape Lifesciences (NASDAQ:RSLS) to $18.50 from $12, citing an improved outlook and lower-than-anticipated share count following it’s merger with Obalon...
H.C. Wainwright initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and price target of $35. The stock closed at $18.73 on June 17. “We believe Sutro Biopharma can continue to be a standout performer...
H.C. Wainwright launched coverage of Metacrine (NASDAQ:MTCR) with a “buy” rating and $15 price target. The stock closed at $4.14 on June 11. Metacrine is a clinical-stage biopharmaceutical company focused on discovering...
Cantor Fitzgerald raised its price target for RAPT Therapeutics (NASDAQ:RAPT) to $71 from $51, citing an increased probability of success for RPT193 in atopic dermatitis to 50% from 25% previously, and taking up peak...
Cantor Fitzgerald launched coverage of CareCloud (NASDAQ:MTBC) with an “overweight” rating and $15 price target. The stock closed at $8.54 on June 10. CareCloud, formerly known as MTBC Inc., provides a broad range of...
Alliance Global Partners initiated coverage of Myomo (NYSEA:MYO) with a “buy” rating and price target of $36.50. The stock closed at $10.19 on June 9. “Myomo, in our view, represents one of the most compelling stories...
H.C. Wainwright launched coverage of UNITY Biotechnology (NASDAQ:UBX) with a “buy” rating and $12 price target. The stock closed at $4.56 on June 4. UNITY is focusing on therapeutics addressing diseases of aging, while...
Raymond James initiated coverage of Alpha Cognition (TSXV:ACOG) with an “outperform” rating and price target of $2.50 (Canadian). The stock closed at 80 cents on June 2. Alpha is in the late stages of clinical...
H.C. Wainwright raised its price target for PDS Biotechnology (NASDAQ:PDSB) to $20 from $8 ahead of additional data being released at the ASCO meeting this weekend. The stock closed at $10.86 on June 1. “We believe that...
Cantor Fitzgerald initiated coverage of Cutera (NASDAQ:CUTR) with an “overweight” rating and 12-month price target of $55. The stock closed at $40.86 on June 1. “Cutera’s comprehensive portfolio of innovative aesthetic...
Cantor Fitzgerald launched coverage of Seelos Therapeutics (NASDAQ:SEEL) with an “overweight” rating and 12-to-18 month price target of $10. The stock closed at $3.08 on May 28. Analyst Charles Duncan, Ph.D., writes...
Cantor Fitzgerald initiated coverage of Harpoon Therapeutics (NASDAQ:HARP) with an “overweight” rating and $40 price target. The stock closed at $20.28 on May 27. Harpoon is an immunoncology company developing a next...
Cantor Fitzgerald launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with an “overweight” rating and 12-month price target of $10. The stock closed at $2.66 on May 26. “We believe that the risk/reward profile is...
Cantor Fitzgerald initiated coverage of Chemomab Therapeutics (NASDAQ:CMMB) with an “overweight” rating and $45 price target. The stock closed at $16.07 on May 25. Chemomab is a clinical-stage biotech company focusing...
H.C. Wainwright launched coverage of Asensus Surgical (NYSE American:ASXC) with a “buy” rating and price target of $4. The stock closed at $2.03 on May 25. Asensus, a surgical robotics company, is digitizing laparoscopy...
William Blair initiated coverage of Vaccitech plc (NASDAQ:VACC) with an “outperform” rating. The stock was quoted at $14.35 in afternoon trading on May 25. Vaccitech is a clinical-stage biotechnology company that...